On March 16, 2026, Quince Therapeutics, Inc. received a notice from the Nasdaq Listing Qualifications department indicating that the closing bid price of the company's common stock had fallen below the minimum requirement of $1.00 per share for continued listing. This notice, referred to as the 'Bid Price Notice', highlights that the company has until September 14, 2026, to regain compliance by ensuring that the bid price closes at $1 or more for at least ten consecutive business days. Failure to meet this requirement could lead to delisting, although the company may be eligible for additional time to regain compliance by transferring its listing to the Nasdaq Capital Market, provided it meets other criteria.

Additionally, on March 17, 2026, Quince Therapeutics received a second notice regarding its market value of listed securities (MVLS), which also fell below the required $50 million threshold for continued listing on the Nasdaq Global Select Market. Similar to the bid price issue, the company has until September 14, 2026, to rectify this situation by maintaining a market value of $50 million or more for a minimum of ten consecutive business days. If compliance is not achieved by the MVLS Compliance Date, the company will receive notification that its securities are subject to delisting.

The company has stated its intention to actively monitor the closing bid price and market value of its common stock and is considering available options to resolve these deficiencies. The notices do not result in immediate delisting, and the company's common stock will continue to trade on the Nasdaq under the symbol 'QNCX'. However, the situation poses significant challenges for Quince Therapeutics, as it navigates the requirements set forth by Nasdaq to maintain its listing status.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.